# MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

> **NCT01437657** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 319 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO4917523 0.5 mg
- **DRUG:** RO4917523 1.5 mg

## Key facts

- **NCT ID:** NCT01437657
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437657, "MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01437657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*